Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease

Journal of Neuroscience

Volumn 25, Issue 42, 2005, Pages 9591-9601

  Marti, Matteo ^a   Mela, Flora ^a   Fantin, Martina ^a   Zucchini, Silvia ^a   Brown, Jeffrey M ^c   Witta, Jassir ^c   Benedetto, Manuela Di ^b   Buzas, Beata ^c   Reinscheid, Rainer K ^d   Salvadori, Severo ^a   Guerrini, Remo ^a   Romualdi, Patrizia ^b   Candeletti, Sanzio ^b   Simonato, Michele ^a   Cox, Brian M ^c   Morari, Michele ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

J 113397; Microdialysis; Neuroprotection; Nociceptin; Parkinson's disease; UFP 101

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTAMIC ACID; HALOPERIDOL; NOCICEPTIN; NOCICEPTIN RECEPTOR; NOCICEPTIN RECEPTOR ANTAGONIST; NOCICEPTIN[N PHENYLALANYLARGINYLLYSINE] AMINE; OXIDOPAMINE; UFP 101; UNCLASSIFIED DRUG;

AKINESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; GENE DELETION; GENE EXPRESSION; HYPOKINESIA; MALE; MOTOR ACTIVITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; SYMPTOM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE DEGENERATION; OPIOID PEPTIDES; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTIC TRANSMISSION;

EID: 27144554951     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2546-05.2005     Document Type: Article

References (48)

1. Aparicio LC, Candeletti S, Binaschi A, Mazzuferi M, Mantovani S, Di Benedetto M, Landuzzi D, Lopetuso G, Romualdi P, Simonato M (2004) Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. J Neurochem 91:30-37.
2. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
3. Bertorelli R, Bastia E, Citterio F, Corradini L, Forlani A, Ongini E (2002) Lack of the nociceptin receptor does not affect acute or chronic nociception in mice. Peptides 23:1589-1596.
4. Bregola G, Zucchini S, Rodi D, Binaschi A, D'Addario C, Landuzzi D, Reinscheid R, Candeletti S, Romualdi P, Simonato M (2002) Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures. J Neurosci 22:10030-10038.
5. 2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol 136:303-311.
6. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N (1997) The neuronal nitric oxide synthase inhibitor also inhibits the monoamine oxidase-B-catalized oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 10:364-368.
7. Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, Hoellt V, Kieffer B, Kitchen I, Mcknight AT, Meunier JC, Portoghese PS (2000) Opioid receptors. In: The IUPHAR compendium of receptor characterization and classification (Girdlestone D, ed), pp 321-333. London: IUPHAR Media.
8. Darland T, Heinricher MM, Grandy DK (1998) Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 21:215-221.
9. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
10. Galeffi F, Bianchi L, Bolam JP, Della Corte L (2003) The effect of 6-hydroxydopamine lesions on the release of amino acids in the direct and indirect pathways of the basal ganglia: a dual microdialysis probe analysis. Eur J Neurosci 18:856-868.
11. Gavioli EC, Marzola G, Guerrini R, Bertorelli R, Zucchini S, De Lima TC, Rae GA, Salvadori S, Regoli D, Calo G (2003) Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci 17:1987-1990.
12. Gerlach M, Riederer P (1996) Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
13. Kawamoto H, Ozaki S, Itoh Y, Miyaji M, Arai S, Nakashima H, Kato T, Ohta H, Iwasawa Y (1999) Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397). J Med Chem 42:5061-5063.
14. Koizumi M, Sakoori K, Midorikawa N, Murphy NP (2004) The NOP (ORL1) receptor antagonist compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism. Br J Pharmacol 143:53-62.
15. Koster A, Montkowski A, Schulz S, Stube EM, Knaudt K, Jenck F, Moreau JL, Nothacker HP, Civelli O, Reinscheid RK (1999) Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci USA 96:10444-10449.
16. Kuzmin A, Sandin J, Terenius L, Ogren SO (2004) Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br J Pharmacol 141:132-140.
17. Laudenbach V, Calo G, Guerrini R, Lamboley G, Benoist JF, Evrard P, Gressens P (2001) Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain. J Clin Invest 107:457-466.
18. Lindner MD, Cain CK, Plone MA, Frydel BR, Blaney TJ, Emerich DF, Hoane MR (1999) Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 102:1-16.
19. Lundblad M, Vaudano E, Cenci MA (2003) Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 84:1398-1410.
20. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M, Noda T, Takahashi T, Sugimoto T, Nabeshima T, Takeshima H (1998) Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature 394:577-581.
21. Marti M, Guerrini R, Beani L, Bianchi C, Morari M (2002a) Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat. Neuroscience 112:153-160.
22. Marti M, Mela F, Bianchi C, Beani L, Morari M (2002b) Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors. J Neurochem 83:635-644.
23. Marti M, Stocchi S, Paganini F, Mela F, De Risi C, Calo G, Guerrini R, Barnes TA, Lambert DG, Beani L, Bianchi C, Morari M (2003) Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex. Br J Pharmacol 138:91-98.
24. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, Rizzi A, Franchi G, Beani L, Bianchi C, Morari M (2004a) Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. J Neurosci 24:6659-6666.
25. Marti M, Mela F, Guerrini R, Calo G, Bianchi C, Morari M (2004b) Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. J Neurochem 91:1501-1504.
26. Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF (1999) Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience 88:1-16.
27. 1 receptor. Nature 377:532-535.
28. Murphy NP, Lam HA, Chen Z, Pintar JE, Maidment NT (2002) Heroin-induced locomotion and mesolimbic dopamine release is unchanged in mice lacking the ORL.1 receptor gene. Brain Res 953:276-280.
29. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM (2004) The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 188:471-479.
30. Neal Jr CR, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson Jr SJ (1999) Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol 406:503-547.
31. Nicotra A, Parvez S (2002) Apoptotic molecules and MPTP-induced cell death. Neurotoxicol Teratol 24:599-605.
32. Nishi M, Houtani T, Noda Y, Mamiya T, Sato K, Doi T, Kuno J, Takeshima H, Nukada T, Nabeshima T, Yamashita T, Noda T, Sugimoto T (1997) Unrestrained nociceptive response and dysregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J 16:1858-1864.
33. Noda Y, Mamiya T, Nabeshima T, Nishi M, Higashioka M, Takeshima H (1998) Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J Biol Chem 273:18047-18051.
34. Norton CS, Neal CR, Kumar S, Akil H, Watson SJ (2002) Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems. J Comp Neurol 444:358-368.
35. Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complication in Parkinson's disease. Trends Neurosci 23:52-7.
36. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. San Diego: Academic.
37. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Sydney: Academic.
38. Ploj K, Roman E, Gustavsson L, Nylander I (2000) Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res Bull 53:219-226.
39. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma Jr FJ, Civelli O (1995) Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270:792-794.
40. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L (2004) Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 20:1255-1266.
41. Rozas G, Guerra MJ, Labandeira-Garcia JL (1997) An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2:75-84.
42. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. Behav Neurosci 102:748-759.
43. Schwarting RKW, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275-331.
44. Simonato M, Bregola G, Donatini A, Bianchi C, Beani L, Ferri S, Romualdi P (1996) Kindled seizure-induced c-fos and prodynorphin mRNA expressions are unrelated in the rat brain. Eur J Neurosci 8:2064-2067.
45. Starr MS (1995) Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse 19:264-293.
46. Takada M, Matsumura M, Kojima J, Yamaji Y, Inase M, Tokuno H, Nambu A, Imai H (2000) Protection against dopaminergic nigrostriatal cell death by excitatory input ablation. Eur J Neurosci 12:1771-1780.
47. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H (1991) Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418.
48. Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485-493.